Nurix Therapeutics, Inc.
Nurix Therapeutics is a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing targeted protein degradation medicines. Its pipeline includes wholly owned and partnered drug candidates for cancer and inflammatory diseases, built around its DEL-AI discovery engine and ligase expertise.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaInternal pipeline assets in clinical development for oncology and inflammatory disease.
Programs advanced with pharmaceutical partners under collaboration and license agreements.
Earlier-stage degrader and DAC programs generated from the DEL-AI discovery engine.
Tuotteet
Raportoitu · osuus liikevaihdosta- Collaboration Revenue64,3 %
- License Revenue35,7 %
Lähde: 10-K FY2025, yhtiön tuotelinjoittain raportoima liikevaihto (SEC XBRL). Osuudet on laskettu näytetyistä riveistä ja ne summautuvat 100 %:iin.
Asiakkaat
Nurix’s direct counterparties are pharmaceutical partners that license, fund, or co-develop degrader programs, including Gilead, Sanofi, and Pfizer. If approved, its medicines would be sold to healthcare systems, insurers, and other payors serving patients with cancer or inflammatory diseases.
Large pharma companies that license targets or co-develop degrader programs under collaboration agreements.
Government and private payors that would reimburse approved products and influence uptake.
Hospitals, clinics, and specialists that would prescribe or administer approved therapies.
The ultimate users of Nurix’s drug candidates if they are approved and commercialized.
Strategia
Nurix’s strategy is to advance its lead degrader programs through clinical development while expanding the DEL-AI platform into additional targets and degrader modalities. It also uses collaborations to share development risk, generate non-product revenue, and preserve optionality for co-development or U.S. profit sharing on selected assets.
Clinical proof-of-concept is the main value driver for a pre-commercial biotech.
Collaborations can offset R&D spend and validate the platform with major pharma partners.
A broader target base increases the chance of finding differentiated drug candidates.
Maantiede
Nurix is headquartered in Brisbane, California and operates as a U.S.-based biotechnology company. Its collaborations and trademark footprint extend internationally, with reported trademark registrations in Canada, Europe, Japan, Mexico, the United Kingdom, and the United States. Commercial exposure would be global if any candidates are approved, but current operations are centered in the United States.
Riskit
Nurix faces the typical risks of a clinical-stage biotech: clinical failure, regulatory setbacks, manufacturing scale-up issues, and dependence on external funding before product sales begin. Its platform also competes in a crowded field of protein degradation and other advanced therapeutic modalities, where larger companies may have more resources and faster development capabilities.
- Clinical development failureVaikutus: KorkeaTodennäköisyys: Kohtalainen
Drug candidates may not demonstrate sufficient safety or efficacy in trials.
Kohdistuu: Lead programs and partnered pipeline
- Regulatory delay or refusalVaikutus: KorkeaTodennäköisyys: Kohtalainen
FDA or other agencies may require more data, impose holds, or reject filings.
Kohdistuu: All clinical-stage assets
- Financing dependenceVaikutus: KorkeaTodennäköisyys: Kohtalainen
The company has no approved products and must fund long development timelines.
Kohdistuu: Corporate liquidity and program continuity
- Manufacturing and supply chain disruptionVaikutus: KorkeaTodennäköisyys: Matala
Early-stage third-party manufacturing can face scale-up, quality, or contamination issues.
Kohdistuu: Clinical trial supply and future commercial supply
- Competitive pressureVaikutus: KeskitasoTodennäköisyys: Kohtalainen
Other protein degradation, antibody, gene therapy, and small-molecule programs may reach market first.
Kohdistuu: BTK degrader and immunology/oncology targets
Kirjanpito
Harkinnanvaraiset erätPayments from partners may be recognized over time or at specific milestones depending on performance obligations.
Vaikutus: Can cause uneven quarterly revenue
Clinical trial, CRO, and manufacturing costs are often accrued before invoices are finalized.
Vaikutus: Affects operating expense and period comparability
A meaningful portion of employee compensation is equity-based in a development-stage biotech.
Vaikutus: Raises reported operating expenses without cash outflow
Net operating losses and uncertain future profitability require a full valuation allowance.
Vaikutus: Limits recognition of tax benefits on the balance sheet
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
CytomX Therapeutics, Inc.
CTMX · Pharmaceutical Preparations
CytomX Therapeutics is a clinical-stage biopharmaceutical company built around its PROBODY platform, which masks biologic drug activity until it reaches the tumor microenvironment.
Immix Biopharma, Inc.
IMMX · Pharmaceutical Preparations
NRX Pharmaceuticals, Inc.
NRXP · Pharmaceutical Preparations
GRI Bio, Inc.
GRI · Pharmaceutical Preparations
XORTX Therapeutics Inc.
XRTX · Pharmaceutical Preparations
Nektar Therapeutics
NKTR · Pharmaceutical Preparations
Nektar Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing immunotherapy medicines for autoimmune disease and cancer.
Päivitetty: 24.9.2026